Table 2 Cognitive outcome measures.

From: Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial

   

CBD

Placebo

CBD vs. Placebo

  
  

Screening visit

Post-cannabis

Post-cannabis

Mean difference

P value

Corrected P value

HVLT-R

Immediate recall

19.3 (17.2 to 21.4)

14.7 (12.8 to 16.7)

16.6 (14.6 to 18.5)

−1.8 (−3.5 to −0.2)

0.04

0.14

 

Immediate intrusions

0.9 (0.6 to 1.2)

2.1 (0.9 to 3.2)

1.9 (0.8 to 3.1)

0.1 (−0.8 to 1.0)

0.80

0.80

 

Immediate repetitions

1.3 (0.7 to 2.0)

1.2 (0.4 to 2.0)

1.7 (0.9 to 2.5)

−0.5 (−1.4 to 0.4)

0.29

0.40

 

Delayed recall

5.2 (4.4 to 6.1)

3.5 (2.5 to 4.5)

4.8 (3.8 to 5.9)

−1.3 (−2.0 to −0.6)

0.001

NA

 

Delayed intrusions

0.5 (0.2 to 0.8)

0.8 (0.1 to 1.5)

1.1 (0.4 to 1.8)

−0.3 (−1 to 0.3)

0.3

0.40

 

Delayed repetitions

0.2 (0.0 to 0.3)

0.2 (−0.1 to 0.5)

0.4 (0.1 to 0.7)

−0.2 (−0.5 to 0.0)

0.07

0.19

Digit Span

Forward

5.9 (5.6 to 6.3)

5.9 (5.5 to 6.4)

6.2 (5.7 to 6.7)

−0.3 (−0.6 to 0.1)

0.12

0.25

 

Reverse

3.9 (3.6 to 4.3)

3.7 (3.3 to 4.2)

3.7 (3.2 to 4.1)

0.1 (−0.4 to 0.6)

0.74

0.80

  1. Data are mean (95% CI).
  2. NA Not applicable.